Louis Fehrenbacher1,2, Reena S Cecchini1,3, Charles E Geyer1,4, Priya Rastogi1,5, Joseph P Costantino1,3, James N Atkins1,6, John P Crown1,7,8, Jonathan Polikoff1,9, Jean-Francois Boileau1,10, Louise Provencher1,11, Christopher Stokoe1,12, Timothy D Moore1,13, André Robidoux1,14, Patrick J Flynn1,15, Virginia F Borges1,16, Kathy S Albain1,17, Sandra M Swain1,18, Soonmyung Paik1,19, Eleftherios P Mamounas1,20, Norman Wolmark1. 1. NRG Oncology, Pittsburgh, PA. 2. Kaiser Permanente Oncology Clinical Trials Northern CA, Novato, CA. 3. University of Pittsburgh, Pittsburgh, PA. 4. Houston Methodist Cancer Center, Houston, TX. 5. University of Pittsburgh Cancer Institute, Pittsburgh, PA. 6. Southeast Clinical Oncology Research-National Cancer Institute Community Oncology Research Program, Richmond, VA. 7. Irish Cooperative Oncology Research Group/Cancer Trials Ireland, Dublin, Ireland. 8. St Vincent's University Hospital, Dublin, Ireland. 9. Kaiser Permanente Southern California, San Diego, CA. 10. McGill University, Montréal, Québec, Canada. 11. Université Laval, Québec City, Québec, Canada. 12. US Oncology Plano, Plano, TX. 13. The Mark H. Zangmeister Center, Columbus, OH. 14. Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada. 15. Minnesota Community Oncology Research Consortium, St Louis Park, MN. 16. University of Colorado Denver, Denver, CO. 17. Loyola University, Maywood, IL. 18. Georgetown University Medical Center, Washington, DC. 19. Yonsei University College of Medicine, Seoul, Republic of Korea. 20. Orlando Health UF Health Cancer Center, Orlando, FL.
Abstract
PURPOSE:Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in patients with HER2-negative breast cancer. PATIENTS AND METHODS: A total of 3,270 women with high-risk primary IBC were randomly assigned to CRx with or without 1 year of trastuzumab. Eligibility criteria included immunohistochemistry (IHC) score 1+ or 2+ with fluorescence in situ hybridization ratio (FISH) < 2.0 or, if ratio was not performed, HER2 gene copy number < 4.0. CRx was either docetaxel plus cyclophosphamide or doxorubicin and cyclophosphamide followed by weekly paclitaxel for 12 weeks. RESULTS: At a median follow-up of 46 months, the addition of trastuzumab to CRx did not improve IDFS (5-year IDFS: 89.8% with CRx plus trastuzumab [CRxT] v 89.2% with CRx alone; hazard ratio [HR], 0.98; 95% CI, 0.76 to 1.25; P = .85). These findings did not differ by level of HER2 IHC expression, lymph node involvement, or hormone-receptor status. For distant recurrence-free interval, 5-year estimates were 92.7% with CRxT compared with 93.6% for CRx alone (HR, 1.10; 95% CI, 0.81 to 1.50; P = .55) and for overall survival (OS) were 94.8% with CRxT and 96.3% in CRx alone (HR, 1.33; 95% CI, 0.90 to 1.95; P = .15). There were no unexpected toxicities from the addition of trastuzumab to CRx. CONCLUSION: The addition of trastuzumab to CRx did not improve IDFS, distant recurrence-free interval, or OS in women with non-HER2-overexpressing IBC. Trastuzumab does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer.
RCT Entities:
PURPOSE: Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in patients with HER2-negative breast cancer. PATIENTS AND METHODS: A total of 3,270 women with high-risk primary IBC were randomly assigned to CRx with or without 1 year of trastuzumab. Eligibility criteria included immunohistochemistry (IHC) score 1+ or 2+ with fluorescence in situ hybridization ratio (FISH) < 2.0 or, if ratio was not performed, HER2 gene copy number < 4.0. CRx was either docetaxel plus cyclophosphamide or doxorubicin and cyclophosphamide followed by weekly paclitaxel for 12 weeks. RESULTS: At a median follow-up of 46 months, the addition of trastuzumab to CRx did not improve IDFS (5-year IDFS: 89.8% with CRx plus trastuzumab [CRxT] v 89.2% with CRx alone; hazard ratio [HR], 0.98; 95% CI, 0.76 to 1.25; P = .85). These findings did not differ by level of HER2 IHC expression, lymph node involvement, or hormone-receptor status. For distant recurrence-free interval, 5-year estimates were 92.7% with CRxT compared with 93.6% for CRx alone (HR, 1.10; 95% CI, 0.81 to 1.50; P = .55) and for overall survival (OS) were 94.8% with CRxT and 96.3% in CRx alone (HR, 1.33; 95% CI, 0.90 to 1.95; P = .15). There were no unexpected toxicities from the addition of trastuzumab to CRx. CONCLUSION: The addition of trastuzumab to CRx did not improve IDFS, distant recurrence-free interval, or OS in women with non-HER2-overexpressing IBC. Trastuzumab does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer.
Authors: David Cameron; Martine J Piccart-Gebhart; Richard D Gelber; Marion Procter; Aron Goldhirsch; Evandro de Azambuja; Gilberto Castro; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Nedal Al-Sakaff; Sabine Lauer; Eleanor McFadden; Brian Leyland-Jones; Richard Bell; Mitch Dowsett; Christian Jackisch Journal: Lancet Date: 2017-02-17 Impact factor: 79.321
Authors: Robert D Mass; Michael F Press; Steven Anderson; Melody A Cobleigh; Charles L Vogel; Noël Dybdal; Grazyna Leiberman; Dennis J Slamon Journal: Clin Breast Cancer Date: 2005-08 Impact factor: 3.225
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: Suthinee Ithimakin; Kathleen C Day; Fayaz Malik; Qin Zen; Scott J Dawsey; Tom F Bersano-Begey; Ahmed A Quraishi; Kathleen Woods Ignatoski; Stephanie Daignault; April Davis; Christopher L Hall; Nallasivam Palanisamy; Amber N Heath; Nader Tawakkol; Tahra K Luther; Shawn G Clouthier; Whitney A Chadwick; Mark L Day; Celina G Kleer; Dafydd G Thomas; Daniel F Hayes; Hasan Korkaya; Max S Wicha Journal: Cancer Res Date: 2013-02-26 Impact factor: 12.701
Authors: Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett Journal: J Clin Oncol Date: 2018-05-30 Impact factor: 44.544
Authors: L Arnould; M Gelly; F Penault-Llorca; L Benoit; F Bonnetain; C Migeon; V Cabaret; V Fermeaux; P Bertheau; J Garnier; J-F Jeannin; B Coudert Journal: Br J Cancer Date: 2006-01-30 Impact factor: 7.640
Authors: Kristen C Blanton; Allison M Deal; Kathleen A Kaiser-Rogers; Carey K Anders; Siobhan M O'Connor; Johann D Hertel; Benjamin C Calhoun Journal: Ann Diagn Pathol Date: 2020-08-08 Impact factor: 2.090
Authors: Patricia A Ganz; Reena S Cecchini; Louis Fehrenbacher; Charles E Geyer; Priya Rastogi; John P Crown; Michael P Thirlwell; David M Ellison; Jean-Francois Boileau; Patrick J Flynn; Jong-Hyeon Jeong; Eleftherios P Mamounas; Norman Wolmark Journal: NPJ Breast Cancer Date: 2021-05-20
Authors: Kathryn J Ruddy; Daniel J Schaid; Anthony Batzler; Reena S Cecchini; Ann H Partridge; Aaron Norman; Louis Fehrenbacher; Elizabeth A Stewart; Emanuel Trabuco; Elizabeth Ginsburg; Fergus J Couch; Peter A Fasching; Celine Vachon; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2021-08-02 Impact factor: 13.506